Skip to content
Sign in

FTXH · NASDAQ · ETF

First Trust Nasdaq Pharmaceuticals ETF (FTXH) Price, Holdings & Fees

$1,100.64+0.64%+$7.00End-of-day price as of Oct 9, 2026

First Trust Nasdaq Pharmaceuticals ETF (FTXH) closed at $1,100.64 on Oct 9, 2026, up 0.64% from the previous close of $1,093.64.

Share price, past year

1Y +18.65%

52-week range $893.50 – $1,100.64. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$1,100.64
Sep 30, 2026$1,048.34
Aug 31, 2026$1,003.78
Jul 31, 2026$947.81
Jun 30, 2026$959.27
May 29, 2026$929.41
Apr 30, 2026$912.91
Mar 31, 2026$971.10
Feb 27, 2026$955.54
Jan 30, 2026$960.67
Dec 31, 2025$936.30
Nov 28, 2025$971.31
Oct 31, 2025$938.67

Key statistics

Expense ratio
0.60%
as of Mar 31, 2025
Net assets
$36.2M
as of Jun 30, 2026
Holdings
51
as of Jun 30, 2026
52-week range
$893.50 – $1,100.64

First Trust Nasdaq Pharmaceuticals ETF's expense ratio is 0.60%: $60.00 a year on $10,000 invested.

Holdings

First Trust Nasdaq Pharmaceuticals ETF held 51 investments worth $36.24M as of Jun 30, 2026. Its largest holding was ELI LILLY & COMPANY, at 7.77% of the fund.

First Trust Nasdaq Pharmaceuticals ETF largest holdings by share of net assets
#Holding% of fundValue
1ELI LILLY & COMPANYLLY7.77%$2.82M
2ABBVIE INCABBV7.39%$2.68M
3MERCK & COMPANY INCMRK7.07%$2.56M
4JOHNSON & JOHNSONJNJ6.96%$2.52M
5BRISTOL-MYERS SQUIBB COMPANYBMY6.29%$2.28M
6BIOGEN INCBIIB3.84%$1.39M
7VIATRIS INCVTRS3.62%$1.31M
8CARDINAL HEALTH INCCAH3.53%$1.28M
9VERTEX PHARMACEUTICALS INCVRTX3.41%$1.23M
10AMGEN INCAMGN3.18%$1.15M
11PFIZER INCPFE2.97%$1.08M
12GILEAD SCIENCES INCGILD2.89%$1.05M
13UNITED THERAPEUTICS CORPUTHR2.72%$987.21K
14REGENERON PHARMACEUTICALS INCREGN2.72%$984.57K
15JAZZ PHARMACEUTICALS PLCJAZZ2.49%$901.47K
16INCYTE CORPINCY2.39%$866.98K
17ILLUMINA INCILMN1.98%$718.79K
18ZOETIS INCZTS1.87%$676.71K
19EXELIXIS INCEXEL1.72%$625.06K
20CHARLES RIVER LABORATORIES INTERNATIONAL INCCRL1.49%$539.08K
21MEDPACE HOLDINGS INCMEDP1.41%$511.58K
22PTC THERAPEUTICS INCPTCT1.37%$496.84K
23NEUROCRINE BIOSCIENCES INCNBIX1.37%$495.32K
24ALKERMES PLCALKS1.35%$490.73K
25HALOZYME THERAPEUTICS INCHALO1.21%$437.76K

Top 25 of 51 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

First Trust Nasdaq Pharmaceuticals ETF holdings by asset type
Asset type% of fund
Stocks99.90%
Cash and short-term investments0.10%
First Trust Nasdaq Pharmaceuticals ETF holdings by country, largest 3
Country% of fund
United States95.59%
Ireland3.84%
Bermuda0.57%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jun 30, 2026, First Trust Nasdaq Pharmaceuticals ETF's total return was +11.43%, as reported to the SEC.

First Trust Nasdaq Pharmaceuticals ETF monthly total returns
MonthTotal return
Jun 30, 2026+9.14%
May 31, 2026+3.55%
Apr 30, 2026−1.40%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
First Trust Nasdaq Pharmaceuticals ETF
Ticker
FTXH
Exchange
NASDAQ
Fund type
ETF
Trust
FIRST TRUST EXCHANGE-TRADED FUND VI
SEC series ID
S000053945
SEC CIK
0001552740
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by FIRST TRUST EXCHANGE-TRADED FUND VI, the trust behind First Trust Nasdaq Pharmaceuticals ETF, and cover all of its funds.

Frequently asked questions

What is FTXH's price?

First Trust Nasdaq Pharmaceuticals ETF (FTXH) closed at $1,100.64 on Oct 9, 2026, up 0.64% from the previous close of $1,093.64.

What is FTXH's expense ratio?

First Trust Nasdaq Pharmaceuticals ETF's expense ratio is 0.60%: $60.00 a year on $10,000 invested.

What does FTXH hold?

First Trust Nasdaq Pharmaceuticals ETF held 51 investments worth $36.24M as of Jun 30, 2026. Its largest holding was ELI LILLY & COMPANY, at 7.77% of the fund. Its five largest holdings were ELI LILLY & COMPANY, ABBVIE INC, MERCK & COMPANY INC, JOHNSON & JOHNSON, BRISTOL-MYERS SQUIBB COMPANY.

How has FTXH performed?

Over the 3 months to Jun 30, 2026, First Trust Nasdaq Pharmaceuticals ETF's total return was +11.43%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 21, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Mar 31, 2025. Prices are generated sample data for development. Data sources and disclosures